v3.26.1
Share-based compensation (Details) - CHF (SFr)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Share-based compensation      
Share-based compensation SFr 70,820 SFr 175,283 SFr 280,200
Discontinued operations      
Share-based compensation      
Share-based compensation   327,681 1,514,267
Share-based compensation expense including accelerated vesting of employees equity incentive units   1,500,000  
Discontinued operations as disclosed below      
Share-based compensation      
Accelerated vesting of equity incentive units of employees and Executive Managers transferred to Neurosterix Pharma Sarl   1,158,069  
Research and development expense      
Share-based compensation      
Share-based compensation 970 2,089 30,190
Research and development expense | Discontinued operations      
Share-based compensation      
Share-based compensation   113,709 540,470
General and administration expense      
Share-based compensation      
Share-based compensation SFr 69,850 173,194 250,010
General and administration expense | Discontinued operations      
Share-based compensation      
Share-based compensation   SFr 213,972 SFr 973,797